1,720,993 research outputs found
Platelet indices and stroke
No full textBASARAN, OZCAN/0000-0002-6384-6455WOS: 000429341700003PubMed ID: 2961986
Associated Factors with Left Atrial Enlargement in Patients with Acute Ischemic Stroke
No full textBASARAN, OZCAN/0000-0002-6384-6455WOS: 000425581800029PubMed ID: 29445062[No abstract available
Forgotten predictors in sepsis
No full textBASARAN, OZCAN/0000-0002-6384-6455WOS: 000380752400103PubMed ID: 2732485
Management of peripartum cardiomyopathy
No full textBASARAN, OZCAN/0000-0002-6384-6455WOS: 000345232200129PubMed ID: 25456691[No abstract available
Late recovery in peripartum cardiomyopathy
No full textBASARAN, OZCAN/0000-0002-6384-6455WOS: 000354905600092PubMed ID: 25839633[No abstract available
What Is the Optimal Timing for Surgical Treatment of Infective Endocarditis?
No full textBASARAN, OZCAN/0000-0002-6384-6455WOS: 000350588500016PubMed ID: 25744120[No abstract available
Does ivabradine really limit dobutamine-induced tachycardia in stable heart failure patients: Parallax in significance
No full textBASARAN, OZCAN/0000-0002-6384-6455; Mert, Kadir Ugur/0000-0002-1331-5365;WOS: 000345232200134PubMed ID: 25456579[No abstract available
Takotsubo cardiomyopathy or Kounis syndrome or both?
No full textBASARAN, OZCAN/0000-0002-6384-6455; Mert, Kadir Ugur/0000-0002-1331-5365;WOS: 000346089400007PubMed ID: 25464395[No abstract available
Anticoagulation Therapy
No full textThe available parenteral and oral anticoagulants have a large clinical use. Understanding biochemistry of anticoagulants may help to improve therapeutic strategies. Resistance to vitamin K antagonist drugs might be a problem for rodent populations. Patients who have thrombogenic risk factors should be anticoagulated. The need for cardiac implantable electronic devices is increasing, and there is a substantial number of patients who are on oral anticoagulant therapy. Prothrombin complex concentrate and other plasma concentrates are useful to deal with over-coagulated situations. The efficacy and safety of non-vitamin K antagonist oral anticoagulants have been proven in large phase III trials. The real-world data suggest even better outcomes with these agents compared to vitamin K antagonists
- …
